FDA is eliminating the $350,000 tag on pediatric medication
May 14, 2019
Until now, Adults and children who suffer from a rare disease called Lambert-Eaton myasthenic syndrome (LEMS) had to pay $350,000 for a drug called Firdapse manufactured by Catalyst Pharmaceutical, but now the FDA has approved an alternate medication developed by Jacobus Pharmaceutical Co., called Ruzurgi. In the US, only 400 people suffer from LEMS, making the drug very difficult to manufacture and store; Jacobus has been testing Ruzurgi for the past few years to make the treatment more affordable for patients, especially children, and patients are hoping to use the drug off-label. The LEMS community is relieved after the FDA's announcement, but the company hasn't announced the price on the drug.